Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

Psoriasis is a common skin disease which bears a substantial impact on patients’ quality of life. Biological agents are prescribed to treat moderate-to-severe cases of psoriasis and in recent years an uneven uptake of biologics has been observed and analyzed in Sweden.

In this study, we scrutinized whether variations in treatment patterns occur between different types of healthcare provider. We compared the use of biologics between university hospitals, non-university hospitals, and individual practices, while accounting for patient characteristics and disease severity. The study detected an uneven uptake of biologics in Swedish clinical practice, but the type of healthcare provider cannot explain this variation.